Kornimate/medical-research-clean huggingface dataset:
efficacy of am-111 in patients with acute sensorineural hearing loss

Conditions: Hearing Loss

Summary: the purpose of the study is to determine whether am-111 is effective in the treatment of acute inner ear hearing loss (acute sensorineural hearing loss, asnhl).


Eligibility criteria:
inclusion criteria: * patients with unilateral acute sensorineural hearing loss (asnhl) with onset 48 hours or less ago * mean earing loss compared with the unaffected contralateral ear of at least 30 db in the 3 most affected contiguous frequencies * age ≥ 18 years and ≤ 60 years * negative pregnancy test for women of childbearing potential * able to attend the on-study visits * written informed consent before participation in the study exclusion criteria: * bilateral asnhl, if not resulting from acoustic trauma * suspected perilymph fistula or membrane rupture * barotrauma * average air bone gap higher than 20 db in 3 contiguous frequencies * history of meniere disease, autoimmune hearing loss, radiation-induced hearing loss, endolymphatic hydrops, suspected retro-cochlear lesion or fluctuating hearing loss * previous asnhl incident within the past 6 weeks * evidence of acute or chronic otitis media or otitis externa on examination * any drug-based therapy for inner ear hearing loss that is ongoing or was performed in the past 2 weeks * any ongoing or planned concomitant medication for the treatment of tinnitus until 30 days after administration * any therapy known as ototoxic (e.g. aminoglycosides, cisplatin, loop diuretics, quinine etc.) in the past 6 months prior to study inclusion * history of drug abuse or alcoholism * any clinically relevant respiratory, cardiovascular, neurological (except vertigo or tinnitus), or psychiatric disorders * known hypersensitivity, allergy or intolerance to the study medication or any history of severe abnormal drug reaction * women who are breast-feeding, pregnant or who plan a pregnancy during the trial * women of childbearing potential who declare being unwilling or unable to practice contraception such as combined oral contraceptives, injectables, hormonal intra-uterine devices, vasectomised partner or sexual abstinence * concurrent participation in another clinical trial or participation in another clinical trial within 30 days prior to study entry * any current anticoagulant therapy (e.g. aspirin, marcumar, etc)

Keywords: sudden hearing loss sudden deafness acoustic trauma noise trauma
multisensory integration and cognitive awareness in post-stroke unilateral spatial neglect

Conditions: Neglect, Hemispatial; Stroke Acute

Summary: the primary aim of this study is to investigate whether multisensory integration (msi) mechanisms observed in patients with right hemisphere lesions without neglect remain intact compared to patients with unilateral spatial neglect (usn). this study also allows for a direct comparison between results from paper-based tests and computerized tests, as well as between patients with right hemisphere lesions without neglect and usn patients. the secondary objectives are: to compare these results in order to obtain a more refined definition of usn at both the unisensory level (as computerized tests are rarely used in hospital settings but have proven effective in diagnosing usn) and the multisensory level (since usn is not generally tested in the auditory modality). to measure eye movements in all patients in the study, as this can provide useful information for characterizing patient deficits.


Eligibility criteria:
inclusion criteria: * patients will be included in the study if they have: * right hemisphere stroke * presence of usn assessed through the apple cancellation * age between 18 and 85 years * signed informed consent * both male and female participants as a control group, patients will also be included if they have: * right hemisphere stroke * absence of usn assessed through the apple cancellation * age between 18 and 85 years * signed informed consent * both male and female participants. exclusion criteria: * both patients with usn and control patients will be excluded if they: * are minors * are unable to give their consent to participate in the study * have significant language deficits (production and comprehension) (e.g., unable to give a verbal response or understand instructions) * have hemianopia * have severe hearing impairments that cannot be corrected (e.g., with hearing aids) * have severe uncorrected visual impairments (e.g., glaucoma) * have a history of psychiatric disorders or substance abuse.

Keywords: neglect attention awareness multisensory integration
pioglitazone versus metformin as first treatment in infertile women with polycystic ovary syndrome

Conditions: Pioglitazone

Summary: participants with pcos will be divided into two groups then each group will randomly recieve one of the following treatment 1. metformin will be adminstered in adose of 500 mg 3 times daily for 3 months to group b. 2. pioglitazone will be administered in adose of 30 mg dialy for 3 months to group a. 3. induction of ovulation by clomiphene citate 50 mg tablets to all participants

participants with pcos will be divided into two groups then each group will randomly recieve one of the following treatment 1. metformin will be adminstered in adose of 500 mg 3 times daily for 3 months to group b. 2. pioglitazone will be administered in adose of 30 mg dialy for 3 months to group a. 3. induction of ovulation by clomiphene citate 50 mg tablets once or twice dialy 12hours apart starting from the 3rd day of menstrual cycle and continue for five days during treatment with insulin sensitizing agents to group a and b. participants with oligomenorrhea will recieve two tablets of noreththisterone 5 mg tab every 12 hours for 5 days to allow for withdrawal bleeding before start ovulation induction

Eligibility criteria:
inclusion criteria: * women age 20_35 * bmi 18_29.9 * women with pcos(diagnosed by using rotterdam criteria * infertility is cause for seeking tfeatment exclusion criteria: * causes of infertility other than pcos. * patient refusal. * contraindication of any of the drugs used in the study * cause of oligo/anovulation other than pcos * current or previous (within the last six month) use of oral contraceptives, glucocorticoids, antiandrogens, antidiabetics, antiobesity drugs or other hormonal drugs.
strength and range of motion in women undergoing surgery for breast cancer

Conditions: Breast Cancer

Summary: rationale: gathering information about strength and range of motion over time from women undergoing surgery for breast cancer may help doctors learn more about recovery from surgery and on-going care. purpose: this clinical trial is collecting information about strength and range of motion over time from women undergoing surgery for breast cancer.

objectives: * collect data regarding diagnosis, type of surgery, receipt of adjuvant therapy, age, height, weight, waist circumference, arm strength, grip strength, shoulder range of motion, and physical activity participation from women undergoing surgery for breast cancer. * examine changes in physical activity participation, measures of body composition, shoulder range of motion, grip strength, and arm strength over time in these patients. * determine differences in changes in physical activity and indices of fitness according to type of surgery and adjuvant therapy. * examine relationships between exercise participation, fitness, and body composition over time. * correlate data with an ongoing randomized exercise trial that includes strength and flexibility assessments with no pre-surgery measures. outline: this is a prospective, cohort study. patients submit data comprising demographic/medical information, anthropometrics (weight, height, waist circumference), grip strength, bicep strength, shoulder range of motion, and physical activity participation prior to surgery, at each surgical follow-up visit, and at 2 years after surgery.

Eligibility criteria:
inclusion criteria: * diagnosis of breast cancer * stage i-iv disease * planning to undergo surgery at the comprehensive cancer center breast clinic at wake forest university baptist medical center

Keywords: long-term effects secondary to cancer therapy in adults recurrent breast cancer stage i breast cancer stage ii breast cancer stage iiia breast cancer stage iiib breast cancer stage iiic breast cancer stage iv breast cancer
cerebral dynamic perfusion study with spectral ct in patients suspected of stroke

Conditions: Stroke, Acute

Summary: * generate a dynamic mapping of the distribution of iodine within the cerebral parenchyma in the patient suspected of acute ischemic disorder with the ct spectral scanner. * correlate the anomalies of iodine mapping to the other parameters acquired during the classic dynamic infusion phase to define the ischemic area (mtt higher and rcbv normal) versus infarcted zone (mtt higher and rcbv decreased)


Eligibility criteria:
inclusion criteria: * clinical suspicion of hyperacute stroke (6 hours after onset of symptoms) * age between 50 and 95 years * weight: between 65 and 95 kg exclusion criteria: * documented or suspected allergy to iv iodinated contrast media * renal impairment with creatinine clearance \<60 ml / min * hemorrhagic lesions or vascular abnormalities demonstrated on ct before contrast injection
efficacy of antihistamine dosing-up and add-on treatment with h2-receptor antagonist

Conditions: Chronic Urticaria

Summary: a randomized open labeled trial to compare the efficacy of antihistamine dosing-up and add-on treatment with h2-receptor antagonist in patients with chronic urticaria

* for four weeks * after the researcher confirms the selection / exclusion criteria on the baseline, the uas, k-uct, and cu-qol are created and randomized from the subject. * receive uas, k-uct, and cu-qol from the subject during the last visit to assess safety

Eligibility criteria:
inclusion criteria: * adolescents and adults over 12 years * clinical diagnosis of chronic urticaria due to wheal reaction, itching, angioedema over 6 weeks * antihistamine 2 or 2 kinds of treatment for more than 2 weeks even if the symptoms are not controlled * those who do not have other chronic skin diseases exclusion criteria: * none

Keywords: cu
study to evaluate the effect of food on the pharmacokinetics of asc41 in healthy volunteers

Conditions: Healthy; NAFLD; Hyperlipidemia

Summary: this study is to evaluate the effect of food on the pharmacokinetics of a single dose of asc41 tablet in healthy volunteers, comparing fasting and postprandial pharmacokinetic parameters of tmax, cmax, auc0-t, auc0-∞.


Eligibility criteria:
key inclusion criteria: * 19kg/m2 ≤ bmi \<40kg/m2. key exclusion criteria: * a history of thyroid disease. * history of, or current liver disease.

Keywords: healthy volunteers nafld nash hyperlipidemia ldl-c
acute exacerbation of chronic obstructive pulmonary disease inpatient registry study

Conditions: Chronic Obstructive Pulmonary Disease

Summary: the purpose of this study is to investigate the demographic characteristics, clinical features, diagnoses and treatments of aecopd hospitalized patients in china, and disease prognosis and its economic burden.


Eligibility criteria:
inclusion criteria: ≥18 years of age; hospitalized patients with main diagnosis as aecopd. exclusion criteria: patients diagnosed as active pulmonary tuberculosis, or acute left heart failure; patients participating in clinical trials or intervention studies of drugs.
comparison between posterior retroperitoneoscopic adrenalectomy and laparoscopic adrenalectomy

Conditions: Adrenal Disease

Summary: the purpose of this study is to compare two surgical methods of adrenalectomy. one is called pra(posterior retroperitoneal adrenalectomy), which is performed through 3 or 4 holes at patient's back. the other is la(laparoscopic adrenalectomy) which is performed through patient's abdominal cavity after making 3 or 4 holes in the abdomen.

since 1992, transabdominal la(laparoscopic adrenalectomy) has been a standard method of adrenalectomy. this traditional method has been used widely because this procedure provides wide view of the whole abdomen which is familiar to surgeons. but due to its unique location at retroperitoneum, adrenal is still not easy to approach. so various retroperitoneal approaches were designed and adjusted. among those, pra(posterior retroperitoneal adrenalectomy) has showed good outcomes in many institutes. pra facilitates direct approach to kidney and adrenal gland, and so operative time can be shortened. but there has been no randomized controlled trial between these two methods. therefore, as experienced surgeons in both methods, we want to practice this study.

Eligibility criteria:
inclusion criteria: * patients who are expected to have benign adrenal disease at preoperative exams * patients who have pheochromocytoma measured less than 5cm, and the other benign adrenal tumors less than 7cm in diameter in preoperative ct scan * patients who do not have previous surgery history at the interested quadrant * patients who is i or ii grade in asa classification(american society of anesthesiologists' physical status classification) * patients who has tolerable liver function and renal function(bilirubin\<2.0mg/dl and ast, alt, serum creatinine within twice of upper normal range, coagulation panel : within normal limit) * patients whose bmi(body mass index) is less than 35 * patients who are supposed to have normal cognitive function * patients who signed the consent paper. exclusion criteria: * patients who are expected to have malignant or metastatic adrenal tumor at preoperative exams * patients who have bilateral adrenal tumors * patients who have condition to undergo the other operation at the abdomen together with adrenalectomy * pregnant patients * patients who have active or uncontrolled infection * patients who have medical problems as below * uncontrollable hypertension with medication(systolic bp\>150 or diastolic bp\>100) * angina, congestive heart failure, acute myocardial infection * history of coronary angioplasty or coronary artery bypass graft surgery * history of stroke, transient ischemic attack with sequela

Keywords: pheochromocytoma aldosteronism cushing's syndrome adrenal incidentaloma conn's syndrome
chaamp (charlotte african american mgus project) internal pilot study

Conditions: Multiple Myeloma; Multiple Myeloma Progression; Monoclonal Gammopathy of Undetermined Significance (MGUS); Smoldering Multiple Myeloma (SMM); Plasma Cell Disorders

Summary: the purpose of this study is to identify multiple myeloma in the precancerous mgus stage in order to reduce the risk of delayed diagnosis of multiple myeloma, decrease morbidity related to multiple myeloma at progression, and improve long term outcomes.

the chaamp internal pilot is a pilot and feasibility study conducted to evaluate the feasibility of the trial methods before a full-scale screening effort is launched. black and/or african american adults 30 years of age or older residing in charlotte or surrounding area will be screened for mgus over one-year period with a target enrollment of 1665 participants. individuals screening positive for monoclonal gammopathy will be provided a clinic referral for further diagnostic evaluation to confirm mgus, smm, or other pcd-related disorder, and will be given the opportunity to consent for the longitudinal portion of the study. participants diagnosed with mgus and smoldering multiple myeloma will be prospectively followed for 10 years per protocol. participants diagnosed with other plasma cell disorders will have their diagnosis and baseline data captured in the registry and followed for overall survival only.

Eligibility criteria:
screening inclusion criteria: * self-identify as black and/or african american * age 30 years or older at the time of consent * capable and willing to provide informed consent. note: hipaa (health insurance portability and accountability act) authorization for the release of personal health information may be included in the informed consent or obtained separately * reside in charlotte, nc, or the surrounding area, based on self-report screening exclusion criteria: * self-reported history of mgus, smm, mm, al amyloidosis, plasma cell leukemia, solitary plasmacytoma, waldenstrom macroglobulinemia, and poems. longitudinal inclusion criteria: * test positive for monoclonal gammopathy during screening portion of the study * consent to the longitudinal portion of the study longitudinal exclusion criteria: * the participant previously underwent diagnostic work up as part of chaamp internal pilot that did not result in a diagnosis of mgus, smoldering multiple myeloma or other non-plasma cell disorder.

Keywords: multiple myeloma hematology plasma cell disorders
the lipid profile of the skin surface in acne

Conditions: Acne

Summary: the purpose of this study is to evaluate the differences in the skin lipid profile of patients with and without acne. secondly, the goal is to learn more about what the effects of retinoinds (topical and systemic) are on the the skin lipid profile. we hypothesize that the skin lipid profile of subjects with acne will be lower in inflammatory lipids in comparison to subjects without acne.

skin lipid profile will be conducted via sebutapes- adhesive tapes that painlessly absorbs sebum from the face. these tapes will be placed on the face for 1 hour. a photograph of the face will be taken during each study visit. a sebumeter will also be used to measure skin sebum secretion rate.

Eligibility criteria:
inclusion criteria: * age 12 to 30 years * have been prescribed tretinoin or isotretinoin exclusion criteria: * those who have taken isotretinoin (systemic) * those who used tretinoin or other topical retinoid within two weeks of starting the study * those with seborrheic dermatitis, rosacea, or polycystic ovary syndrome * those who are pregnant, prisoners, or cognitively impaired * those who do not fit the inclusion criteria

Keywords: acne lipid tretinoin isotretinoin
a study of lenvatinib plus nivolumab in participants with hepatocellular carcinoma

Conditions: Carcinoma, Hepatocellular

Summary: the primary objective of this study is to evaluate the tolerability and safety of a combination of lenvatinib plus nivolumab in participants with hepatocellular carcinoma (hcc).


Eligibility criteria:
inclusion criteria: * participants must have confirmed diagnosis of hepatocellular carcinoma (hcc) with any of the following criteria: * histologically or cytologically confirmed diagnosis of hcc, excluding fibrolamellar, sarcomatoid or mixed cholangio-hcc tumors * clinically confirmed diagnosis of hcc according to american association for the study of liver diseases criteria, including cirrhosis of any etiology and/or chronic hepatitis b or c infection * part 1: hcc for which no other appropriate therapy is available; part 2: no prior systemic therapy for advanced/unresectable hcc * participants categorized to stage b (not applicable for transarterial chemoembolization), or stage c based on barcelona clinic liver cancer staging system * child-pugh score a * participants must have an eastern cooperative oncology group performance status of 0 to 1 * age greater than or equal to (\>=) 20 years at the time of informed consent exclusion criteria: * active co-infection with hepatitis b and hepatitis c * participants with any active, known, or suspected autoimmune disease * participants being treated with drugs that strongly inhibit or induce cyp3a4 and that may be possibly used during this study * females who are breastfeeding or pregnant
a study of electrocardiogram and focused cardiac ultrasound for enhanced cardiac disease screening

Conditions: Cardiac Disease

Summary: the purpose of this study is to evaluate and compare the effectiveness of active screening for shd in asymptomatic outpatients referred for an ecg, using a combination of ai-ecg and focus. invites will be sent and participants enrolled electronically.


Eligibility criteria:
inclusion criteria: * adult patients (\>18 years of age) * echocardiogram is not clinically indicated exclusion criteria: * prior history of congenital or acquired shd, as defined by the following 1. aortic stenosis: 2. heart failure 3. left ventricular dysfunction 4. cardiac amyloidosis 5. hypertrophic cardiomyopathy (hcm) 6. rheumatic heart disease 7. congenital heart disease * recent (within last 12 months) echocardiogram * scheduled clinically indicated future echocardiogram * inability to provide informed consent to participate in the study
pseudoxanthoma elasticum (pxe) natural history biomarkers in pxe individuals and their biological non-pxe siblings

Conditions: Pseudoxanthoma Elasticum

Summary: this pxe biomarker study aims to characterize the levels of inorganic pyrophosphate (ppi), pyridoxal 5´-phosphate (plp), and other biomarkers relevant to pxe and ectopic calcification in both pxe patients and their biological siblings who are pxe carriers or normal non-pxe individuals.

this non-interventional pxe study is designed to assess differences in circulation levels of selective biomarkers related to pxe and tissue-nonspecific alkaline phosphatase (tnap) inhibition, between pxe patients, pxe carriers, and non-pxe normal individuals.

Eligibility criteria:
inclusion criteria: * male or female participants aged 18 to 75 years * participants (approximately 1 carrier and 1 normal to match proband) * confirmed pxe participants: index pxe/proband with established pxe and abcc6 mutations identified * pxe carrier participants: biological sibling of the pxe index case and confirmed as pxe carrier * non-pxe normal participants: biological sibling of pxe index case and confirmed as non-pxe normal exclusion criteria: * unconfirmed abcc6 mutation status * use of bisphosphonate in the preceding 12 months and during the study * use of vitamin b6 and/or vitamin d supplement in the preceding 1 month and during the study (if the total vitamin b6 supplementation is \>5 mg/day) * recent initiation or dose change of vitamin d and/or multivitamin supplement in the preceding 1 month and during the study * bone fracture within 3 months prior to screening or active bone disease (excluding osteopenia or osteoporosis) * history of hyperparathyroidism * history of moderate to severe renal impairment * history of hypophosphatasia * known history of uncorrected abnormality in calcium (ca), phosphate, alkaline phosphatase (alp) or parathyroid hormone * other significant condition (medical, psychiatric, social, or medication) that, in the judgment of the investigator, would prevent full participation or would be inappropriate for the study

Keywords: pseudoxanthoma elasticum bone turnover biomarkers tissue mineralization biomarkers